GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achillion Pharmaceuticals Inc (NAS:ACHN) » Definitions » Shiller PE Ratio

Achillion Pharmaceuticals (Achillion Pharmaceuticals) Shiller PE Ratio : (As of May. 14, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Achillion Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Achillion Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Achillion Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achillion Pharmaceuticals Shiller PE Ratio Chart

Achillion Pharmaceuticals Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Achillion Pharmaceuticals Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Achillion Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Achillion Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Achillion Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achillion Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Achillion Pharmaceuticals's Shiller PE Ratio falls into.



Achillion Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Achillion Pharmaceuticals's E10 for the quarter that ended in Sep. 2019 is calculated as:

For example, Achillion Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2019 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2019 (Change)*Current CPI (Sep. 2019)
=-0.14/108.3294*108.3294
=-0.140

Current CPI (Sep. 2019) = 108.3294.

Achillion Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200912 -0.250 91.111 -0.297
201003 -0.160 91.821 -0.189
201006 -0.170 91.962 -0.200
201009 -0.150 92.162 -0.176
201012 -0.100 92.474 -0.117
201103 -0.170 94.283 -0.195
201106 -0.190 95.235 -0.216
201109 -0.150 95.727 -0.170
201112 -0.180 95.213 -0.205
201203 -0.130 96.783 -0.146
201206 -0.160 96.819 -0.179
201209 -0.200 97.633 -0.222
201212 -0.140 96.871 -0.157
201303 -0.140 98.209 -0.154
201306 -0.210 98.518 -0.231
201309 -0.140 98.790 -0.154
201312 -0.140 98.326 -0.154
201403 -0.170 99.695 -0.185
201406 -0.160 100.560 -0.172
201409 -0.160 100.428 -0.173
201412 -0.215 99.070 -0.235
201503 -0.170 99.621 -0.185
201506 -0.250 100.684 -0.269
201509 0.190 100.392 0.205
201512 0.120 99.792 0.130
201603 -0.130 100.470 -0.140
201606 -0.140 101.688 -0.149
201609 -0.150 101.861 -0.160
201612 -0.030 101.863 -0.032
201703 -0.150 102.862 -0.158
201706 -0.160 103.349 -0.168
201709 -0.140 104.136 -0.146
201712 -0.170 104.011 -0.177
201803 -0.150 105.290 -0.154
201806 -0.120 106.317 -0.122
201809 -0.120 106.507 -0.122
201812 -0.120 105.998 -0.123
201903 -0.140 107.251 -0.141
201906 -0.140 108.070 -0.140
201909 -0.140 108.329 -0.140

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Achillion Pharmaceuticals  (NAS:ACHN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Achillion Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Achillion Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Achillion Pharmaceuticals (Achillion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
300 George Street, New Haven, CT, USA, 06511
Achillion Pharmaceuticals Inc is a biotechnology company that seeks to discover and commercialize treatments for rare diseases. The company is engaged solely in the discovery and development of innovative small-molecule drug therapies for infectious diseases and immune system disorders. Achillion specializes in structural biology, medicinal chemistry, and antimicrobial discovery research. The company generates revenue from product sales, regulatory and commercialization milestones, and royalties. Achillion also uses collaborative and licensing agreements.
Executives
Joseph Truitt director, officer: Chief Executive Officer C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Kurt Graves director C/O ACHILLION PHARMACEUTICALS INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Michael D Kishbauch director 18 CHERRYVILLE RD, FLEMINGTON NJ 08822
Jason S Fisherman director C/O ADVENT INTERNATIONAL CORP, 75 STATE ST 29TH FLOOR, BOSTON MA 02104
Van Nostrand Robert L director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Nicole Vitullo director 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Martha E Manning officer: General Counsel 700 PENNSYLVANIA DR, EXTON PA 19341
Frank Verwiel director C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Paul E Firuta officer: EVP, Chief Commercial Officer 550 HILLS DRIVE, THIRD FLOOR, BEDMINSTER NJ 07921
Steven Zelenkofske officer: EVP, Chief Medical Officer 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Mary Kay Fenton officer: Chief Financial Officer ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Milind Deshpande director, officer: Chief Executive Officer ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Johnson & Johnson Innovation - Jjdc, Inc. 10 percent owner 410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Johnson & Johnson 10 percent owner ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
David Apelian officer: Chief Medical Officer C/O ACHILLION PHARMACEUTICALS, INC, 300 GEORGE STREET, NEW HAVEN CT 06511